A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN IDH1-MUTANT DIFFUSE GLIOMA: UPDATED RESULTS

被引：1
|
作者：
Mellinghoff, Ingo [1 ]
Wen, Patrick [2 ]
Taylor, Jennie [3 ]
Taylor, Elizabeth [4 ]
Arrillaga-Romany, Isabel [5 ]
Ellingson, Benjamin [6 ]
Mahboub-Johnson, Paria [7 ]
Baron, Eric [7 ]
Hassan, Islam [7 ]
Steelman, Lori [7 ]
Clarke, Jennifer [3 ]
Cloughesy, Timothy [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] UT Southwestern Med Ctr, Dallas, TX USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Servier Pharmaceut, Boston, MA USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae165.0414
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CTNI-47
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Ingo K. Mellinghoff
    Min Lu
    Patrick Y. Wen
    Jennie W. Taylor
    Elizabeth A. Maher
    Isabel Arrillaga-Romany
    Katherine B. Peters
    Benjamin M. Ellingson
    Marc K. Rosenblum
    Saewon Chun
    Kha Le
    Ania Tassinari
    Sung Choe
    Youssef Toubouti
    Steven Schoenfeld
    Shuchi S. Pandya
    Islam Hassan
    Lori Steelman
    Jennifer L. Clarke
    Timothy F. Cloughesy
    Nature Medicine, 2023, 29 : 615 - 622
  • [2] Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Mellinghoff, Ingo K.
    Lu, Min
    Wen, Patrick Y.
    Taylor, Jennie W.
    Maher, Elizabeth A.
    Arrillaga-Romany, Isabel
    Peters, Katherine B.
    Ellingson, Benjamin M.
    Rosenblum, Marc K.
    Chun, Saewon
    Le, Kha
    Tassinari, Ania
    Choe, Sung
    Toubouti, Youssef
    Schoenfeld, Steven
    Pandya, Shuchi S.
    Hassan, Islam
    Steelman, Lori
    Clarke, Jennifer L.
    Cloughesy, Timothy F.
    NATURE MEDICINE, 2023, 29 (03) : 615 - +
  • [3] Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Ingo K. Mellinghoff
    Min Lu
    Patrick Y. Wen
    Jennie W. Taylor
    Elizabeth A. Maher
    Isabel Arrillaga-Romany
    Katherine B. Peters
    Benjamin M. Ellingson
    Marc K. Rosenblum
    Saewon Chun
    Kha Le
    Ania Tassinari
    Sung Choe
    Youssef Toubouti
    Steven Schoenfeld
    Shuchi S. Pandya
    Islam Hassan
    Lori Steelman
    Jennifer L. Clarke
    Timothy F. Cloughesy
    Nature Medicine, 2024, 30 : 302 - 302
  • [4] Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial (vol 29, pg 615, 2023)
    Mellinghoff, Ingo K.
    Lu, Min
    Wen, Patrick Y.
    Taylor, Jennie W.
    Maher, Elizabeth A.
    Arrillaga-Romany, Isabel
    Peters, Katherine B.
    Ellingson, Benjamin M.
    Rosenblum, Marc K.
    Chun, Saewon
    Le, Kha
    Tassinari, Ania
    Choe, Sung
    Toubouti, Youssef
    Schoenfeld, Steven
    Pandya, Shuchi S.
    Hassan, Islam
    Steelman, Lori
    Clarke, Jennifer L.
    Cloughesy, Timothy F.
    NATURE MEDICINE, 2024, 30 (01) : 302 - 302
  • [5] Ivosidenib for IDH1-mutant cholangiocarcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (07): : 647 - 647
  • [6] Ivosidenib effective in IDH1-mutant AML
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2018, 15 : 472 - 472
  • [7] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT, IDH1-MUTANT, LOW-GRADE GLIOMA: RESULTS FROM COHORT 1
    Mellinghoff, I. K.
    Wen, P. Y.
    Taylor, J. W.
    Maher, E. A.
    Arrillaga-Romany, I.
    Peters, K. B.
    Le, K.
    Tai, F.
    Steelman, L.
    Cloughesy, T. F.
    NEURO-ONCOLOGY, 2019, 21 : 2 - 2
  • [8] Ivosidenib for advanced IDH1-mutant cholangiocarcinoma
    Gervaso, Lorenzo
    Pellicori, Stefania
    Fazio, Nicola
    LANCET ONCOLOGY, 2020, 21 (08): : E370 - E370
  • [9] Ivosidenib effective in IDH1-mutant AML
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (08) : 472 - 472
  • [10] An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma
    Tella, Sri Harsha
    Mahipal, Amit
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (17) : 1879 - 1885
12345